Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
NCT01798004
Completed
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/03/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +122 locations
Conditions: Stage 4S Neuroblastoma, Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma
Register for Updates
T-Cell Therapy for Advanced Breast Cancer
NCT02792114
Active Not Recruiting
The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Memorial Sloan Kettering Cancer Center (Consent and follow-up only), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Metastatic HER2-negative Breast
Register for Updates
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
NCT03032783
Recruiting
This phase II trial studies the how well donor stem cell transplant works in treating patients with high risk hematologic malignancies. Giving total-body irradiation and chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT00878254
Active Not Recruiting
The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated Mantle Cell Lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: University of Miami, Miami, Florida
Conditions: Mantle-Cell Lymphoma
Register for Updates
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
NCT00734877
Active Not Recruiting
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3). Note: Randomization has been discontinued and accrual is closed to the L-TT3 arm. This trial is currently enrolling as a single-arm trial for patients to receive S-TT3.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2024
Locations: University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
NCT00869232
Active Not Recruiting
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy. Past studies conducted at the MIRT and at other institutions have shown that participants with high-risk features by gene array studies tend to have shorte... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
NCT03480360
Active Not Recruiting
The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/28/2024
Locations: Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire
Conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
Register for Updates
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
NCT03448978
Terminated
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: The Center for Cancer and Blood Disorders, Bethesda, Maryland +2 locations
Conditions: Multiple Myeloma
Register for Updates
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05000450
Terminated
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Sarah Cannon/Colorado Blood Cancer Institute, Denver, Colorado +3 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
NCT03704298
Terminated
The primary objectives of this study are: Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2 Phase 2: To evaluate the efficacy of axicabtagene ciloleucel and utomilumab as measured by complete response rate in participants with refractory large B-cell lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Stanford Cancer Institute, Palo Alto, California +4 locations
Conditions: Relapsed/Refractory Large B-cell Lymphoma
Register for Updates
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893
Recruiting
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite un... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/21/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma, Mesothelioma, Neuroendocrine Tumors, Squamous Cell Cancer, Merkel Cell Carcinoma, Mismatch Repair Deficiency, Microsatellite Instability
Register for Updates
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
NCT03493854
Completed
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Maryland Oncology Hematology, Rockville, Maryland +106 locations
Conditions: Early Breast Cancer
Register for Updates